Dr Eleanor Cheadle (PhD) - research
My research interests lie in immunotherapy of B-cell malignancies. I am particularly interested in ways to improve the generation of effective anti-tumour T-cell immune responses post anti-CD20 monoclonal antibody therapy. My research currently focuses on a number of ways to improve anti-CD20 mAb therapy such as combining therapy with immunomodulatory agents, radiation and manipulation of the tumour microenvironment. We are particularly interested in the novel type II anti-CD20 mAb Obinutuzumab and how its mechanism of action compares to type I rituximab. I am also interested in adoptive cell therapy, in particular gene modified T-cells expressing CD19 specific chimeric antigen receptors.